CG Oncology, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on August 6, 2026, covering the three- and six-month periods ended June 30, 2026.

Key Highlights

  • Net loss of $79.1 million for the three months ended June 30, 2026, compared to a net loss of $41.4 million in the same period of 2025.
  • Total revenues of $1.157 million for Q2 2026, up from zero in Q2 2025, reflecting the start of commercial and development revenue.
  • Marketable securities of $1.008 billion as of June 30, 2026, up from $709.7 million as of December 31, 2025.
  • Follow-on public offering in Q1 2026 raised net proceeds of approximately $391.4 million through the issuance of 6,941,407 shares of common stock.
  • Research and development expenses totaled $54.7 million for Q2 2026, compared to $31.3 million in Q2 2025.
  • Accumulated deficit of $518.2 million as of June 30, 2026, versus $379.0 million as of December 31, 2025.
  • 88,640,375 shares of common stock outstanding as of August 4, 2026.

CG Oncology's Financial Position and Operating Activity in the First Half of 2026

According to the filing, CG Oncology, Inc. (Nasdaq Global Select Market: CGON), a clinical-stage oncology company incorporated in Delaware and headquartered in Dallas, Texas, reported total revenues of $2.240 million for the six months ended June 30, 2026. The filing shows this figure comprised $2.216 million in commercial and development revenue and $24 thousand in license and collaboration revenue. In the comparable six-month period of 2025, total revenues were $52 thousand, consisting solely of license and collaboration revenue, indicating the company began generating commercial and development revenue in 2026.

The company reported a net loss of $139.3 million for the six months ended June 30, 2026, compared to a net loss of $75.9 million for the same period of 2025, according to the filing. Total operating costs and expenses for the first half of 2026 were $155.0 million, including cost of sales of $6.887 million, research and development expenses of $98.4 million, and general and administrative expenses of $49.8 million. The filing also reported interest income, net of $13.6 million for the first half of 2026, partially offsetting operating losses.

The condensed consolidated balance sheet as of June 30, 2026 reflected total assets of $1.086 billion and total stockholders' equity of $1.029 billion, according to the filing. Cash used in operating activities was $103.4 million for the six months ended June 30, 2026. The company held cash and cash equivalents of $19.6 million and marketable securities of $1.008 billion at period end. The filing noted that net cash provided by financing activities was $394.9 million for the period, driven primarily by the follow-on public offering completed in Q1 2026.

What Was Disclosed

CG Oncology filed a quarterly report disclosing unaudited financial statements for the period ended June 30, 2026, including its balance sheet, income statement, cash flow statement, and related notes, as well as management's discussion and analysis of financial condition and results of operations.